(Q37260272)

19 August 2017

1 reference

title

Early chemotherapy in prostate cancer (English)

1 reference

19 August 2017

1 reference

1 reference

Danish Mazhar

1

1 reference

19 August 2017

Jonathan Waxman

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

published in

Nature Reviews Urology

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

486-493

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro1204

19 August 2017

exact match

0 references

cites work

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Nomograms as predictive models

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Improving outcomes in early prostate cancer: Part I--adjuvant treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Adjuvant mitozantrone chemotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1204

7 January 2021

Identifiers

DOI

10.1038/NCPURO1204

1 reference

19 August 2017

1 reference